Global Bacterial Pharyngitis Drugs Market - 2024-2031

Overview

The global bacterial pharyngitis drugs market reached US$ 2.5 billion in 2023 and is expected to reach US$ 3.6 billion by 2031, growing with a CAGR of 4.8% during the forecast period 2024-2031.

Bacterial pharyngitis, also known as strep throat, is an infection of the pharynx caused by bacteria, most commonly group A Streptococcus (GAS) or Streptococcus pyogenes. It presents with a sore throat, fever, and swollen lymph nodes in the neck. Other symptoms include white patches on the tonsils and pain with swallowing.

Bacterial pharyngitis is transmitted through airborne droplets or direct contact with infected individuals. It is most common in children aged 5-15, although adults can also be affected. If untreated, bacterial pharyngitis can lead to complications such as rheumatic heart disease and post-streptococcal glomerulonephritis.

In bacterial pharyngitis, bacteria invade the mucosal tissues of the pharynx directly. Extracellular factors such as proteases facilitate tissue invasion and cause inflammation.

Market Dynamics: Drivers

Growing Prevalence of Bacterial Pharyngitis

The demand for the global bacterial pharyngitis drugs market is driven by multiple factors. The increased incidence of pharyngitis, particularly bacterial pharyngitis caused by group A Streptococcus (GAS), is a key driver of the growing bacterial pharyngitis drugs market.

An increase in the bacterial infection rate can help to drive this market growth. The increase in the number of bacterial pharyngitis cases is expected to drive the growth of the market. According to the Cleveland Clinic, in December 2022, it is estimated that about 616 million strep throat cases are reported annually around the world. The condition accounts for 5% to 15% of new cases of sore throat in adults in the U.S. It accounts for 15% to 35% of new cases of sore throat in children in the U.S.

Similarly, in June 2023, the CDC estimated that, in the most recent five years, approximately 14,000 to 25,000 cases of group A strep disease occurred annually in the United States, with 1,500 to 2,300 annual deaths. Also, in March 2024, Japanese health authorities warned about a jump in potentially deadly strep throat infections, with cases running about three times higher than last year in Tokyo. The increase in the cases utilizes the available treatment procedures, driving the market's growth.

Moreover, key players launch new services help to drive this market growth. For instance, in October 2023, Northern Ireland launched a pharmacy sore throat and expanded UTI services. The country will also pilot a new test and treatment service for sore throats in 40 pharmacies, with £265,000 allocated. The NI government said that it anticipates pharmacies will deliver 12,000 consultations for the UTI service and around 8,000 for the sore throat service over the winter period.

Restraints

Factors such as side effects associated with antibiotics, self-medication & antibiotics misuse, stringent regulatory policies, lack of skilled professionals, lack of awareness among individuals, and availability of limited treatment options, are expected to hamper the market.

Segment Analysis

The global bacterial pharyngitis drugs market is segmented based on infection type, bacteria type, drug class, distribution channel, and region.

The Group A streptococcus segment accounted for approximately 56.3% of the global bacterial pharyngitis drugs market share

The Group A streptococcus segment is expected to hold the largest market share over the forecast period. Group A streptococcus is a gram-positive, non-motile bacteria, the most common etiology for acute pharyngitis. Group A strep is highly contagious and is a common type of bacterial pharyngitis that can be spread through respiratory droplets. Group A strep includes symptoms such as sore throat, fever, and swollen lymph nodes.

Group A streptococcus (GAS) bacteria, Streptococcus pyogenes, are Gram-positive beta-hemolytic bacteria of which over 240 emm types (genotypes) have been identified. GAS can be present on the skin and throat, as well as in the vagina or perianal area of asymptomatic carriers. It can also cause a range of clinical presentations in the form of non-invasive and invasive diseases.

Moreover, the rising number of GAS cases globally, and research studies on the developing treatment for bacterial pharyngitis would propel this segment growth. About 10,000-15,000 cases of invasive GAS disease occur in the U.S. yearly, resulting in over 2,000 deaths. Group A strep can lead to further complications such as rheumatic fever.

Also, in February 2024, Bristol researchers are part of a newly launched multi-institution network to research bacterial causes of sepsis and heart damage in children. Each year, around half a million people, including many children and young people, die around the world because of serious group A streptococcal (Strep A) bacterial infections.

In addition, the availability of effective drugs for the treatment of bacterial pharyngitis helps to propel this segment's growth. As per Medscape infectious disease news in August 2023, Oral penicillin is currently the drug of choice for GABHS (group A beta-hemolytic streptococci)pharyngitis. Amoxicillin remains a reliable alternative and offers advantages in terms of easier dosing and increased palatability. Tetracyclines and trimethoprim/sulfamethoxazole should not be used to treat GABHS pharyngitis owing to higher rates of resistance.

Geographical Analysis

North America accounted for approximately 43.2% of the global bacterial pharyngitis drugs market share

North America region is expected to hold the largest market share over the forecast period. The increased prevalence of the infection, the availability of major key players presence in the region, and the increased number of patients suffering from bacterial pharyngitis are primarily driving the market growth in this region.

Canada's public health agency has logged a record number of potentially deadly strep A infections, particularly in children under the age of 15. At least six children have died in Ontario.

Moreover, increased group A streptococcus samples in this region help to demand for bacterial pharyngitis drugs. According to the Public Health Agency of Canada (PHAC) in January 2024, has received more than 4,600 invasive group A streptococcus samples from 2023, which is the highest annual total ever recorded in Canada and a more than 40 percent increase over the previous year peak of 3,236 samples. According to PHAC, invasive group A streptococcus is endemic in the country, with 2,000 to 3,000 cases reported annually in recent years.

In addition, major player's strategies such as partnerships & collaborations, and awareness programs would drive this market growth. For instance, in May 2023, Traditional Medicinals announced a partnership with Dave Matthews Band through sponsorship of REVERB's Eco-Village during the band's U.S. summer concert tour. Dave Matthews has been using Throat Coat tea for years, as part of his throat care routine before performing and while onstage sharing his music with fans.

Through his connection to the Throat Coat brand and REVERB's mission to empower the music community to take meaningful environmental action, Traditional Medicinals saw a values-aligned opportunity to connect people, plants, and the planet through this partnership.

Also, in November 2022, a new global study launched during World Antimicrobial Awareness Week shows a high dependence on antibiotics for treating respiratory conditions like sore throat, which is helping to fuel antibiotic resistance - the third leading cause of death worldwide, associated with 4.95 million deaths a year.

Market Segmentation

By Infection Type

• Acute
• Chronic

By Bacteria Type

• Group A Streptococcus
• Group B Streptococcus
• Group C Streptococcus
• Group D Streptococcus
• Group G Streptococcus

By Drug Class

• NSAIDs
• Anti-Histamines
• Others

By Distribution Channel

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Russia
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the bacterial pharyngitis drugs market include Novartis AG, Aurobindo Pharma, AdvoCare Pharma, Pfizer, Cipla Inc., Aden Healthcare, Teva Pharmaceutical Industries Ltd., Orchid Pharma, Lupin, and Medopharm.

Key Developments

• In March 2024, bioMerieux received U.S. Food and Drug Administration (FDA) 510(k) clearance and clinical laboratory improvement amendments (CLIA) waiver approval for the BIOFIRE SPOTFIRE respiratory/sore throat (R/ST) panel.
• In September 2023, bioMerieux submitted dual 510(k) and CLIA-waiver applications to the FDA for the BIOFIRE SPOTFIRE respiratory/sore throat (R/ST) panel. The SPOTFIRE R/ST panel mini-tests for the 5 most probable viruses or bacteria that cause respiratory and sore throat symptoms, including influenza, rhinovirus, respiratory syncytial virus SARS-CoV-2, and streptococcal pharyngitis.

Why Purchase the Report?

• To visualize the global bacterial pharyngitis drugs market segmentation based on infection type, bacteria type, drug class, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of bacterial pharyngitis drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global bacterial pharyngitis drugs market report would provide approximately 70 tables, 63 figures, and 182 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies